Theratechnologies: Surges on positive data from HIV-associated NASH drug

Theratechnologies

24/07/2020 12:07

** U.S.-listed shares of Canadian pharma co  THTX.O  surge
27.6% to $2.9 premarket; set for their best day in four months
    ** Stock among top pct gainer across U.S. exchanges
    ** Co says new data from a mid-stage trial supports the
potential of its experimental drug, tesamorelin, to treat
HIV-associated nonalcoholic steatohepatitis (NASH) urn:newsml:reuters.com:*:nGNXJJ6DN
    ** NASH is a chronic liver disease characterised by excess
fat, inflammation and cell damage in liver that can cause
fibrosis or scarring of the organ
    ** The data also supports the development of tesamorelin as
a potential treatment for liver diseases - THTX
    ** Up to Thursday's close, stock fallen 32.4 YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))